Kindred Biosciences snags $50 mln debt facility
Kindred Biosciences, a biopharmaceutical company focused on pets, has secured a $50 million debt facility from Solar Capital Partners LLC</strong. Cantor Fitzgerald & Co acted as sole lead arranger and financial adviser to KindredBio on this transaction.
2 October 2019•3 mins read
